| Page 72 | Kisaco Research

AI is redefining how clinical trials are designed and executed. A major obstacle to complete transformation is tapping into the data that offers novel, well-governed insights. Drawing on the industry’s largest trial operations dataset: schedules of assessment, amendment drivers, trial benchmarks, and site performance trends, Advarra offers a unique, ethically grounded data foundation. Building on this vantage point, the session will share a vision for how AI can transform the drug development lifecycle from end to end, along with real-world applications already shaping the future of trials.

Author:

Mike Eckrote

Senior Vice President of Strategic Solutions & Technology
Advarra

Mike Eckrote is Senior Vice President of Strategic Solutions & Technology at Advarra, where he leads efforts to advance innovative approaches to clinical research and development. He brings more than a decade of experience in real-world data, technology solutions, and clinical trial optimization, with leadership roles spanning HealthVerity, Medable, and Medidata Solutions. Throughout his career, Mike has specialized in applying AI/ML, real-world evidence, and data-driven strategies to improve trial design, site selection, and patient outcomes.

... read more

Mike Eckrote

Senior Vice President of Strategic Solutions & Technology
Advarra

Mike Eckrote is Senior Vice President of Strategic Solutions & Technology at Advarra, where he leads efforts to advance innovative approaches to clinical research and development. He brings more than a decade of experience in real-world data, technology solutions, and clinical trial optimization, with leadership roles spanning HealthVerity, Medable, and Medidata Solutions. Throughout his career, Mike has specialized in applying AI/ML, real-world evidence, and data-driven strategies to improve trial design, site selection, and patient outcomes.

The promise of AI in pharma is hindered by fragmented R&D data silos and the infrastructure gap between cloud-native research and on-premise manufacturing. This session presents an architectural blueprint for a unified, hybrid data platform designed to bridge these divides, creating a seamless R&D-to-manufacturing continuum.

We will explore how to first connect R&D data into a powerful knowledge graph. Next, we detail how to compute on this unified data by securely deploying NVIDIA's advanced AI models as microservices within a sovereign cloud environment. Finally, we demonstrate how a true hybrid architecture can bridge the cloud-native lab to the factory floor, unifying CMC and manufacturing data for end-to-end optimization.

Author:

Rameez Chatni

Global Director, AI Solutions, Pharmaceutical & Life Sciences
Cloudera
... read more

Rameez Chatni

Global Director, AI Solutions, Pharmaceutical & Life Sciences
Cloudera

At AIDDD 25, Dirk Van Hyfte and Holly Soutter will share insights on reprogramming the entire drug discovery process, presenting the HYFT® breakthrough that enables biology to "compute itself"—making complex biological connections explainable, accessible, and actionable for the first time. This session will explore: 

  • Reprogramming Discovery: How AI-native platforms are reshaping how scientists interact with biological data and design new therapies. 
  • The HYFT® Breakthrough: Unveiling a novel computational approach that decodes universal biosphere patterns, unlocking unprecedented discovery potential. 
  • The Frontier of Explainable AI in Biology: Transcending black-box models to deliver clarity, transparency, and trust in AI-powered biological research.

Author:

Dirk Van Hyfte MD, PhD

Chief Technology Officer,
MindWalk

Dirk Van Hyfte stands at the forefront of innovation where artificial intelligence and biology intersect. As Chief Technology Officer of MindWalk, a Bio-Native AI company, Dirk leads transformative research powered by patented HYFT® technology and the LensAI™ platform—cutting-edge tools that unify biological data for accelerated drug discovery and development.

 

With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium and a PhD in medical artificial intelligence from Nijmegen University, Dirk combines deep clinical knowledge with pioneering expertise in computational science. Dirk’s expertise extends beyond the realms of technology and business. His entrepreneurial vision is reflected in the creation of iKnow, a natural language processing platform acquired by InterSystems, a global data technology leader, in 2010.

 

Dirk’s leadership has positioned MindWalk as a driving force in explainable and scalable biological AI, moving the field toward an era where biology itself computes, learns, and reveals new therapeutic frontiers.

 

 

At AIDDD 25, Dirk Van Hyfte and Holly Soutter will share insights on reprogramming the entire drug discovery process, presenting the HYFT® breakthrough that enables biology to "compute itself"—making complex biological connections explainable, accessible, and actionable for the first time. This session will explore:

  • Reprogramming Discovery: How AI-native platforms are reshaping how scientists interact with biological data and design new therapies.
  • The HYFT® Breakthrough: Unveiling a novel computational approach that decodes universal biosphere patterns, unlocking unprecedented discovery potential.
  • The Frontier of Explainable AI in Biology: Transcending black-box models to deliver clarity, transparency, and trust in AI-powered biological research.
... read more

Dirk Van Hyfte MD, PhD

Chief Technology Officer,
MindWalk

Dirk Van Hyfte stands at the forefront of innovation where artificial intelligence and biology intersect. As Chief Technology Officer of MindWalk, a Bio-Native AI company, Dirk leads transformative research powered by patented HYFT® technology and the LensAI™ platform—cutting-edge tools that unify biological data for accelerated drug discovery and development.

 

With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium and a PhD in medical artificial intelligence from Nijmegen University, Dirk combines deep clinical knowledge with pioneering expertise in computational science. Dirk’s expertise extends beyond the realms of technology and business. His entrepreneurial vision is reflected in the creation of iKnow, a natural language processing platform acquired by InterSystems, a global data technology leader, in 2010.

 

Dirk’s leadership has positioned MindWalk as a driving force in explainable and scalable biological AI, moving the field toward an era where biology itself computes, learns, and reveals new therapeutic frontiers.

 

 

At AIDDD 25, Dirk Van Hyfte and Holly Soutter will share insights on reprogramming the entire drug discovery process, presenting the HYFT® breakthrough that enables biology to "compute itself"—making complex biological connections explainable, accessible, and actionable for the first time. This session will explore:

  • Reprogramming Discovery: How AI-native platforms are reshaping how scientists interact with biological data and design new therapies.
  • The HYFT® Breakthrough: Unveiling a novel computational approach that decodes universal biosphere patterns, unlocking unprecedented discovery potential.
  • The Frontier of Explainable AI in Biology: Transcending black-box models to deliver clarity, transparency, and trust in AI-powered biological research.

Author:

Holly Soutter

Director, Lead Discovery and Profiling
Broad Institute of MIT and Harvard

Former Director, Lead Discovery and Profiling, Center for the Development of Therapeutics, The Broad Institute of MIT and Harvard

 Dr. Holly Soutter is a visionary leader and driving force in the convergence of biotech, pharma, and artificial intelligence, leveraging over two decades of drug discovery expertise.  Holly's innovation lies in her ability to strategically unify structural biology, biochemistry, and biophysics with cutting-edge high-throughput screening to generate the high-quality data essential for fueling next-generation machine learning models.

She possesses a clear-eyed vision: that the future of drug discovery is AI-powered, but that success hinges on a "biology-first," hypothesis-driven approach to ML integration. This deep commitment ensures that the technology serves the science, accelerating the path to novel therapies.

 While at the Broad Institute, Holly built a legacy of collaboration, working directly with machine learning experts to seamlessly integrate AI tools into hit finding workflows. These pioneering, integrated systems have democratized small molecule discovery, making it accessible to academic researchers worldwide.  As the founding co-chair of the Machine Learning in Drug Discovery Symposium, she acts as a crucial nexus, fostering vital connections between experimentalists and ML scientists and attracting luminaries who are defining the next era of medicine.

 

At AIDDD 25, Dirk Van Hyfte and Holly Soutter will share insights on reprogramming the entire drug discovery process, presenting the HYFT® breakthrough that enables biology to "compute itself"—making complex biological connections explainable, accessible, and actionable for the first time. This session will explore: 

  • Reprogramming Discovery: How AI-native platforms are reshaping how scientists interact with biological data and design new therapies. 
  • The HYFT® Breakthrough: Unveiling a novel computational approach that decodes universal biosphere patterns, unlocking unprecedented discovery potential. 
  • The Frontier of Explainable AI in Biology: Transcending black-box models to deliver clarity, transparency, and trust in AI-powered biological research.
... read more

Holly Soutter

Director, Lead Discovery and Profiling
Broad Institute of MIT and Harvard

Former Director, Lead Discovery and Profiling, Center for the Development of Therapeutics, The Broad Institute of MIT and Harvard

 Dr. Holly Soutter is a visionary leader and driving force in the convergence of biotech, pharma, and artificial intelligence, leveraging over two decades of drug discovery expertise.  Holly's innovation lies in her ability to strategically unify structural biology, biochemistry, and biophysics with cutting-edge high-throughput screening to generate the high-quality data essential for fueling next-generation machine learning models.

She possesses a clear-eyed vision: that the future of drug discovery is AI-powered, but that success hinges on a "biology-first," hypothesis-driven approach to ML integration. This deep commitment ensures that the technology serves the science, accelerating the path to novel therapies.

 While at the Broad Institute, Holly built a legacy of collaboration, working directly with machine learning experts to seamlessly integrate AI tools into hit finding workflows. These pioneering, integrated systems have democratized small molecule discovery, making it accessible to academic researchers worldwide.  As the founding co-chair of the Machine Learning in Drug Discovery Symposium, she acts as a crucial nexus, fostering vital connections between experimentalists and ML scientists and attracting luminaries who are defining the next era of medicine.

 

At AIDDD 25, Dirk Van Hyfte and Holly Soutter will share insights on reprogramming the entire drug discovery process, presenting the HYFT® breakthrough that enables biology to "compute itself"—making complex biological connections explainable, accessible, and actionable for the first time. This session will explore: 

  • Reprogramming Discovery: How AI-native platforms are reshaping how scientists interact with biological data and design new therapies. 
  • The HYFT® Breakthrough: Unveiling a novel computational approach that decodes universal biosphere patterns, unlocking unprecedented discovery potential. 
  • The Frontier of Explainable AI in Biology: Transcending black-box models to deliver clarity, transparency, and trust in AI-powered biological research.
  • Learn how real-world data is transformed into structured, usable intelligence through PRISM (Patient Record Inference & Structuring Module), an AI-enabled engine that converts fragmented, multi-modal patient data into inference-ready patient journeys supporting scalable clinical insights and model validation.

  • Explore how Zephyr’s AI-enabled multi-modal models (AIM Suite) predict drug response and reconstruct gene expression from clinically available inputs, such as NGS data from commercial LDTs and whole-slide images, enabling retrospective and prospective evaluation of treatment predictions across oncologic therapeutic classes.

  • Discover how Zephyr’s AI-driven software accelerates co-development and clinical integration, enabling fine-tuned foundation models to embed directly into R&D workflows while supporting rapid clinical intelligence queries, cohorting, and data-driven decision-making.

Author:

Anshu Jain, MD

Chief Business and Clinical Officer
Zephyr AI

Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.

Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.

He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.

Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.

... read more

Anshu Jain, MD

Chief Business and Clinical Officer
Zephyr AI

Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.

Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.

He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.

Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.

Data powers the engine of artificial intelligence (AI), but not all data is created equal. While software capabilities are rapidly accelerating, the biopharma industry still largely lacks the intelligent hardware needed to generate clean, contextualized, and high-quality data that AI and machine learning (ML) models require to deliver on their promise.

Explore how today’s in silico process development tools for bioreactor scaling and mechanistic modeling of chromatography can help you get it right the first time now, and why the next generation of intelligent hardware will be critical to unlocking the full potential of AI/ML in biopharma.

Author:

Tobias Hahn, PhD

R&D Director, GoSilico
Cytiva

Tobias Hahn is R&D Director of chromatography mechanistic modeling activities at Cytiva. As former co-founder and CEO of GoSilico, now part of Cytiva, Tobias is responsible for delivering simulation software and workflows for in silico process development. He received his undergraduate education in computational mathematics and technical physics in Karlsruhe and Stockholm, earning his PhD in chemical engineering from Karlsruhe Institute of Technology (KIT). During his doctoral studies, he utilized his background in mathematics and software engineering to create the simulation software now known as GoSilico™ chromatography modeling software.

... read more

Tobias Hahn, PhD

R&D Director, GoSilico
Cytiva

Tobias Hahn is R&D Director of chromatography mechanistic modeling activities at Cytiva. As former co-founder and CEO of GoSilico, now part of Cytiva, Tobias is responsible for delivering simulation software and workflows for in silico process development. He received his undergraduate education in computational mathematics and technical physics in Karlsruhe and Stockholm, earning his PhD in chemical engineering from Karlsruhe Institute of Technology (KIT). During his doctoral studies, he utilized his background in mathematics and software engineering to create the simulation software now known as GoSilico™ chromatography modeling software.

Author:

Cilon Li

Sr. Director of Engineering, Digital Products Development
Cytiva

Cilon Li is a digital and IT executive with over 15 years of experience in healthcare and biopharma. He is a strategic leader with a proven track record in driving digital transformation across supply chain management, product management, and R&D. At Cytiva, Cilon drives the company’s digital strategy and expanding product portfolio, encompassing Internet of Things (IoT), data analytics, AI/ML, software as a service (SaaS) and enterprise applications to help customers progress their digital biomanufacturing journeys. 

... read more

Cilon Li

Sr. Director of Engineering, Digital Products Development
Cytiva

Cilon Li is a digital and IT executive with over 15 years of experience in healthcare and biopharma. He is a strategic leader with a proven track record in driving digital transformation across supply chain management, product management, and R&D. At Cytiva, Cilon drives the company’s digital strategy and expanding product portfolio, encompassing Internet of Things (IoT), data analytics, AI/ML, software as a service (SaaS) and enterprise applications to help customers progress their digital biomanufacturing journeys. 

Author:

Andrew Brooked

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.

 

... read more

Andrew Brooked

Chief Technical Officer & Co-Founder
Faculty

Andrew leads Faculty’s technical teams and developed the backbone of Faculty’s AI operating system, Frontier. His accomplishments span building the NHS Covid Early Warning System and mission critical projects for the UK Ministry of Defence. Before Faculty, Andrew led an engineering team at investment management firm BlackRock. He holds a Master’s degree in Computer Science from the University of Warwick.